News
Skilled US imaging of the adnexal mass: Starting point
- Author:
- Steven R. Goldstein, MD
- Ilan E. Timor-Tritsch, MD
Whether you scan the patient yourself or refer her to an ultrasonography lab, you need to be able to identify both physiologic and pathologic...
News
OSTEOPOROSIS
- Author:
- Steven R. Goldstein, MD
New data enhance our understanding of the effects of some contraceptives and key SERMs on the skeletal health of users
News
The case for chemoprevention as a tool to avert breast cancer
- Author:
- Steven R. Goldstein, MD
Women at high risk of invasive breast cancer can elect chemoprevention with tamoxifen or raloxifene. An aromatase inhibitor may one day be an...
News
OSTEOPOROSIS
- Author:
- Steven R. Goldstein, MD
News
OSTEOPOROSIS
- Author:
- Steven R. Goldstein, MD
Recent data refine our understanding of how to use key drugs, particularly bisphosphonates, zoledronic acid, recombinant PTH, and raloxifene
News
Shoulder dystocia: Clarifying the care of an old problem
- Author:
- Steven R. Goldstein, MD
Should maternal pushing stop once dystocia is diagnosed? Here’s light on the standard of care.
News
Does bone loss resume when alendronate is discontinued?
- Author:
- Steven R. Goldstein, MD
News
Osteopenia: When to intervene?
- Author:
- Steven R. Goldstein, MD
Why fracture risk assessment should rely on a constellation of factors—not just a numerical bone-density value
News
Preventing fragility fractures: Effective drugs and doses
- Author:
- Steven R. Goldstein, MD
The latest data from well-designed trials, including FACT, CORE, and MOBILE, have enlightened us on efficacy, tolerability, and patient-friendly...
News
Aromatase inhibitors and breast cancer? Don’t write off tamoxifen
- Author:
- Steven R. Goldstein, MD
News
Reducing the risk of breast cancer: Key trials and their impact on practice
- Author:
- Steven R. Goldstein, MD
An expert sifts the data regarding chemopreventive options and expands on current guidelines for endometrial cancer screening of tamoxifen users...